BioSpace News Archive

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Martin Edwards has been appointed and Richard H. Aldrich is resigning from the Company’s Board of Directors.

Equity research is published in the framework of Frost & Sullivan’s Independent Equity Research Program. Contact us at no cost to learn more about the companies we cover or to tell us about companies you want covered: equity.research@frost.com

CPT Code a key component for reimbursement from private medical insurance and Medicare

Microvi was founded in 2008 by Dr. Fatemeh Shirazi, CEO and CTO.

Nationwide provider of precision health services expands to Lutz, Florida.

Researchers at the University of Colorado find a reduction in the frequency of migraine days and in overall acute medication for chronic migraineurs in trial using the Cefaly medical device

From 13 countries and 24 US states, competitors were judged on the strength of their commercially viable cutting-edge technologies and therapeutic solutions.

Russell 2000® and 3000® Indexes as well as the appropriate growth and value style indexes following the conclusion of the 2019 Russell indexes annual reconstitution.

Zynex will be officially listed on the Index when the markets open on Monday July 1, 2019.

Orders Reflect Growing Interest across the Biotech Industry for Bacteria-Free, Plasmid-Free Therapies